Trends and Disparities in CAR-T Therapy Utilization, Inpatient Mortality, Length of Stay, and Costs in the United States (2017-2022)
{{output}}
Background: Since FDA approval in August 2017, chimeric antigen receptor T-cell (CAR-T) therapy has rapidly transformed the treatment landscape of relapsed or refractory hematologic malignancies. However, national data describing... ...
